Am J Perinatol 2020; 37(11): 1110-1114
DOI: 10.1055/s-0040-1714060
Original Article

Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization

Autoren

  • Michael J. Fassett

    1   Department of Maternal-Fetal Medicine, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California
  • Lawrence D. Lurvey

    2   Southern California Permanente Medical Group, Pasadena, California
  • Lyn Yasumura

    3   Department of Obstetrics and Gynecology, Kaiser Permanente Baldwin Park Medical Center, Baldwin Park, California
  • Marielle Nguyen

    4   Department of Neonatal Medicine, Kaiser Permanente Anaheim Medical Center, Anaheim, California
  • Joseph J. Colli

    5   Department of Neonatal Medicine, Kaiser Permanente South Bay Medical Center, Los Angeles, California
  • Marianna Volodarskiy

    6   Kaiser Foundation Hospitals, Pasadena, California
  • Jonathan C. Gullett

    7   Southern California Permanente Medical Group Regional Reference Laboratories, North Hollywood, California
  • David Braun

    8   Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
  • Alex Fong

    9   Department of Maternal-Fetal Medicine, Kaiser Permanente Irvine Medical Center, Irvine, California
  • Neha Trivedi

    10   Department of Maternal-Fetal Medicine, Kaiser Permanente San Diego Medical Center, San Diego, California
  • Katia Bruxvoort

    8   Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
  • Vicki Chiu

    8   Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
  • Darios Getahun

    8   Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
    11   Department of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California

Funding This study was supported by Kaiser Permanente Direct Community Benefit Funds.

Abstract

Objective The coronavirus disease 2019 (COVID-19) pandemic has created a need for data regarding the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnant women. After implementing universal screening for COVID-19 in women admitted for delivery, we sought to describe the characteristics of COVID-19 in this large cohort of women.

Study Design An observational study of women admitted to labor and delivery units in Kaiser Permanente Southern California (KPSC) hospitals between April 6 and May 11, 2020 who were universally offered testing for SARS-CoV-2 infection (n = 3,963). Hospital inpatient and outpatient physician encounter, and laboratory records were used to ascertain universal testing levels, test results, and medical and obstetrical histories. The prevalence of SARS-CoV-2 infection was estimated from the number of women who tested positive during labor per 100 women delivered.

Results Of women delivered during the study period, 3,923 (99.0%) underwent SARS-CoV-2 testing. A total of 17 (0.43%; 95% confidence interval: 0.23–0.63%) women tested positive, and none of them were symptomatic on admission. There was no difference in terms of characteristics between SARS-CoV-2 positive and negative tested women. One woman developed a headache attributed to COVID-19 3 days postpartum. No neonates had a positive test at 24 hours of life.

Conclusion The findings suggest that in pregnant women admitted for delivery between April 6 and May 11, 2020 in this large integrated health care system in Southern California, prevalence of SARS-CoV-2 test positive was very low and all patients were asymptomatic on admission.

Key Points

  • The prevalence of SARS-CoV-2 infection in a large diverse cohort of term pregnant women was 0.43%.

  • 99% of women accepted SARS-CoV-2 screening on admission to labor and delivery.

  • All women with positive test results were asymptomatic at the time of testing.



Publikationsverlauf

Eingereicht: 28. Mai 2020

Angenommen: 11. Juni 2020

Artikel online veröffentlicht:
03. Juli 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.